Stay updated on Fovista + Lucentis vs Lucentis: Safety Efficacy Clinical Trial
Sign up to get notified when there's something new on the Fovista + Lucentis vs Lucentis: Safety Efficacy Clinical Trial page.
![Latest website image capture](/pages/_next/image?url=https%3A%2F%2Fs3.us-west-2.amazonaws.com%2Fvp-files-ore%2Fresources%2F12months%2FDo7XSfMoBwrplOQJx5_EWuQSDCs.uncropped.jpg&w=3840&q=75)
Latest updates to the Fovista + Lucentis vs Lucentis: Safety Efficacy Clinical Trial page
- CheckyesterdayNo Change Detected
- Check2 days agoNo Change Detected
- Check3 days agoNo Change Detected
- Check4 days agoChange DetectedThe study has expanded to include 115 locations, and the revision has been updated from v2.9.7 to v2.10.0.SummaryDifference0.4%
- Check5 days agoNo Change Detected
- Check11 days agoChange DetectedThe website has been updated to Revision v2.9.7 from v2.9.6.SummaryDifference0.1%
- Check25 days agoChange DetectedThe value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent revision in the content of the webpage.SummaryDifference0.1%
- Check30 days agoChange DetectedThe value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent revision in the content of the webpage.SummaryDifference0.1%
- Check31 days agoChange DetectedThe value of Revision has been updated from v2.9.1 to v2.9.3, indicating a recent revision in the content of the webpage.SummaryDifference0.1%
- Check32 days agoChange DetectedThe value 'Show more Show more Revision: v2.9.0' has recently changed to 'Show less MedlinePlus Genetics related topics: Age-related macular degeneration MedlinePlus related topics: Macular Degeneration Drug Information available for: Ranibizumab FDA Drug and Device Resources Show less Design Details Primary Purpose : Treatment Allocation : Randomized Interventional Model : Parallel Assignment Masking : Quadruple ( Participant Care Provider Investigator Outcomes Assessor ) Arms and Interventions Participant Group/Arm Intervention/Treatment Experimental : E10030 + ranibizumab E10030 1.5 mg intravitreal injection + ranibizumab 0.5 mg intravitreal injection Drug : E10030 Other Names: Fovista® Drug : ranibizumab Other Names: Lucentis® Active Comparator : Sham + ranibizumab E10030 sham intravitreal injection + ranibizumab 0.5 mg intravitreal injection Drug : ranibizumab Other Names: Lucentis® Drug : E10030 sham intravitreal injection Pressure on the eye with a syringe with no needle Other Names: Sham Primary Outcome Measures Outcome Measure Measure Description Time Frame Mean Change in Visual Acuity From Baseline to 12 Months The primary efficacy endpoint is the mean change in visual acuity (ETDRS letters) from baseline to the month 12 visit. Higher ETDRS letters represents higher vision and a higher change in ETDRS letters represents better functioning. 12 Months Keywords Provided by Astellas Pharma Inc (Ophthotech Corporation) Wet AMD choroidal neovascularization Fovista® E10030 Lucentis® Additional Relevant MeSH Terms Retinal Degeneration Retinal Diseases Eye Diseases Macular Degeneration Angiogenesis Inhibitors Angiogenesis Modulating Agents Growth Substances Physiological Effects of Drugs Growth Inhibitors Antineoplastic Agents Ranibizumab Plan to Share Individual Participant Data (IPD)? No IPD Plan Description There is no plan to share individual participant data at this time Revision: v2.9.1'SummaryDifference13%
Stay in the know with updates to Fovista + Lucentis vs Lucentis: Safety Efficacy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fovista + Lucentis vs Lucentis: Safety Efficacy Clinical Trial page.